Form 4: ARS Pharmaceuticals CEO Richard Lowenthal Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
Richard Lowenthal, CEO of ARS Pharmaceuticals, executed sales of common stock on February 29, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- Richard E. Lowenthal, the President and CEO of ARS Pharmaceuticals, sold shares of common stock on February 29, 2024.
- The sales were executed under a Rule 10b5-1 trading plan established on March 31, 2023.
- He sold shares at weighted average prices ranging from $9.0144 to $9.0190.
- The sales were conducted in multiple transactions, with prices ranging between $9.00 and $9.10.
- Lowenthal also indirectly owns shares through various trusts, including charitable remainder unitrusts and a family trust.
- Following the reported transactions, Lowenthal directly owns 4,126,822 shares of common stock.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock sales by an executive. It doesn't inherently convey positive or negative sentiment, as it's simply a factual disclosure.
Industry Context
This filing is a routine disclosure of insider trading activity. It's common for executives to use 10b5-1 plans to sell shares over time to avoid accusations of trading on inside information.
Stakeholder Impact
- The stock sales by the CEO could potentially create short-term selling pressure on the stock.
- The sales are being conducted under a pre-arranged plan, which should mitigate concerns about insider information being used.
Key Dates
| Date | Description |
|---|---|
| 2006-04-03 | Date of Lowenthal-Tanimoto Family Trust U/A DTD |
| 2020-01-07 | Date of Richard E. Lowenthal Charitable Remainder UniTrust and Sarina Tanimoto Charitable Remainder UniTrust |
| 2023-03-31 | Date of adoption of Rule 10b5-1 trading plan |
| 2024-02-29 | Date of stock sale transactions |
| 2024-03-01 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.